Try our Advanced Search for more refined results
Life Sciences
- 
									October 30, 2025
									Med Robot Co. Tells 9th Circ Not To Revive 'Disfavored' SuitIntuitive Surgical urged the Ninth Circuit not to revive a surgical repair company's claims alleging it blocked third parties from refurbishing components for its popular da Vinci surgery robot, defending the district court's findings that cases alleging anticompetitive harm to a single brand aftermarket are "rare and disfavored." 
- 
									October 30, 2025
									Fiber Optics Co. Agrees To Reforms To End Derivative SuitFiber optic equipment company Luna Innovations Inc. has reached a deal with its investors to settle their derivative claims alleging the company was damaged by its failure to properly recognize revenue in its filings with the U.S. Securities and Exchange Commission. 
- 
									October 30, 2025
									Avantor Minimized Competition On Lab Biz, Investor SaysBiotech company Avantor Inc. was hit with a proposed securities class action in Pennsylvania federal court Thursday alleging it misled investors when it minimized the effects of increased competition on its business and operations while touting strong competitive positioning, causing stock prices to plunge when the truth came out. 
- 
									October 30, 2025
									Fed. Circ. Explains Rule While Upholding Merck PTAB LossThe Federal Circuit sided with generics makers Thursday and upheld the Patent Trial and Appeal Board's invalidation of claims in two Merck KGaA patents on the blockbuster multiple sclerosis drug Mavenclad, while clarifying how to treat invalidity arguments that involve overlapping inventors. 
- 
									October 30, 2025
									2nd Ex-Magellan Exec Avoids Jail Over Faulty Lead TestsA second former Magellan Diagnostics executive ducked prison time Thursday for his role in an alleged scheme to hide a defect in the company's lead-testing devices ahead of its sale in 2016. 
- 
									October 30, 2025
									Lawmakers Slam Value-Based Patent Fee ProposalSix members of the U.S. House of Representatives wrote to U.S. Secretary of Commerce Howard Lutnick on Thursday expressing concern over the proposal to charge patent holders fees based on their patent's value, saying that will harm innovation and economic growth. 
- 
									October 30, 2025
									J&J's Janssen Says 3rd Circ. Should Reverse $1.6B FCA WinJohnson & Johnson's Janssen Products LP urged the Third Circuit to overturn a $1.6 billion False Claims Act judgment over two of its HIV drugs, arguing the district court allowed whistleblowers to prove fraud based solely on "off-label" marketing rather than any false claim actually submitted to the government. 
- 
									October 30, 2025
									Generic-Drug Firms Want To Fast-Track Conn. Price Cap FightAn industry group for generic and biosimilar pharmaceutical companies has asked a Connecticut federal judge to fast-track its lawsuit seeking to block the state's new drug price cap, claiming it will suffer "imminent harm" if the case is delayed. 
- 
									October 30, 2025
									McCarter & English Used Doctrine As 'Whipsaw,' Panel HearsA biotech company on Thursday urged a New Jersey appellate panel to revive its legal malpractice suit against McCarter & English LLP, arguing that the claims were distinct from the firm's own suit seeking unpaid fees. 
- 
									October 30, 2025
									Mich. Top Court Upholds Gilead Immunity In COVID Drug CaseThe Michigan Supreme Court on Wednesday said it won't consider an appeal from a man who was injected with a COVID-19 treatment made by Gilead Sciences Inc. that was later recalled for containing glass shards, a few months after a lower appellate court found the company immune because of a federal health emergency law. 
- 
									October 30, 2025
									Judge Unpauses 'Important' Suit Over Vax GuidelinesA Massachusetts federal judge agreed Thursday to lift a government shutdown-related stay of litigation challenging new COVID-19 vaccine recommendations for children and pregnant women, calling the case a "matter of national importance" that warrants keeping the case moving over the U.S. Department of Justice's objection. 
- 
									October 30, 2025
									Novo Nordisk Bids $9B For Metsera, Jeopardizing Pfizer DealMetsera Inc. said Thursday that Novo Nordisk has put forth a $9 billion buyout proposal that is "superior" to its existing agreement to sell itself to Pfizer, prompting a response from Pfizer stating that it is prepared to "pursue all legal avenues" to keep its agreement intact. 
- 
									October 29, 2025
									DOJ Subpoena Called 'Pressure' To Ax Gender-Affirming CareThe U.S. Department of Justice issued a subpoena to intimidate a telehealth organization into ending gender-affirming medical care, a Seattle federal judge said in a ruling that found the agency is using the guise of an investigation to further the Trump administration's stated goal of eliminating transgender and gender-diverse patients' access to healthcare. 
- 
									October 29, 2025
									DexCom Misled Investors About Its Diabetes Tech, Suit SaysMedical device maker DexCom is facing a proposed investor class action in Manhattan federal court alleging the company hurt shareholders by failing to disclose changes to a glucose monitoring device affecting the reliability of the device's readings. 
- 
									October 29, 2025
									Conn. Med Spa Says Ex-Workers Poaching Clients, EmployeesTwo former employees of a Connecticut medical spa violated their employment contract when they lured a co-worker to join them at a nearby competitor and began soliciting the spa's clients, a state court lawsuit alleges. 
- 
									October 29, 2025
									Where PTAB Institution Reviews Stand As Squires Takes LeadU.S. Patent and Trademark Office Director John Squires will be maintaining the agency leader's new role of gatekeeper at the Patent Trial and Appeal Board. Here's what to know about his plans and the pushback on them. 
- 
									October 29, 2025
									Taro Pharma Beats Investor Suit Over $43-Per-Share BuyoutA New York federal judge tossed a proposed class action brought by minority shareholders of Taro Pharmaceutical Industries Ltd. that alleged the company and its majority shareholder misled them during the approval process for a $43-per-share buyout, finding the minority shareholders have failed to plead any actionable misstatements or omissions. 
- 
									October 29, 2025
									Ga. Panel Backs Sanctions For 'Delaying Tactic' In Pot DisputeThe Georgia Court of Appeals on Wednesday backed sanctions rulings against two companies that filed litigation after they were denied cannabis licenses by Georgia, only to draw out the proceedings for years before dropping their claims at "quite literally the last minute." 
- 
									October 29, 2025
									FDA Unveils Plan To Speed Biosimilar Drugs To MarketThe Trump administration on Wednesday said it plans to slash the cost of biologics by shortening the time required to bring a biosimilar drug to market and making it easier for patients to switch to the cheaper products. 
- 
									October 29, 2025
									3 Pharmaceutical Firms Will Pay $4M To Tribes In Opioid MDLIndivior, Sun Pharmaceuticals and Zydus Pharmaceuticals have inked deals to compensate tribes for their role in the opioid crisis, according to stipulated dismissals entered on Wednesday in Ohio federal court. 
- 
									October 29, 2025
									Brothers Found Guilty Of $100M HIV Drug FraudA Florida federal jury on Wednesday convicted two Maryland brothers accused of conspiring to distribute about $100 million worth of misbranded HIV drugs, finding them guilty of fraud charges related to selling the medication with fake tracing documents. 
- 
									October 29, 2025
									PE-Backed Medical Supplies Giant Medline Files For IPOPrivate equity-backed medical supplies giant Medline has filed for its long-awaited initial public offering, eyeing a return to public markets four years after being taken private through a large buyout. 
- 
									October 29, 2025
									'Smart Drugs' Amphetamine Suit Moves Forward Minus ExecsA Washington federal judge declined to trim claims from a former army nurse's suit alleging that Thesis "smart drugs" contained amphetamines without warning consumers, while dismissing her claims against two executives for the company. 
- 
									October 29, 2025
									3 Firms Guide Thermo Fisher On $8.9B Clario DealThermo Fisher Scientific Inc. said on Wednesday it will acquire Clario Holdings Inc., a provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg, Nordic Capital, Novo Holdings and Cinven for $8.875 billion in cash. 
- 
									October 28, 2025
									Off-Label Prescribing Was Common, Novo Nordisk Tells JuryA whistleblower suing drugmaker Novo Nordisk for allegedly defrauding Washington state's Medicaid system acknowledged from the witness stand Tuesday that she previously prescribed hemophilia drugs for off-label use in her own practice — despite concerns she raised in her lawsuit about other doctors' off-label prescription of Novo Nordisk's drug NovoSeven. 
Editor's Picks
- 
									Supreme Court Will Tackle Patent Enablement In Amgen CaseThe U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the law's history, accepting Amgen's request to consider how much a patent must disclose in order to meet enablement requirements. 
- 
									A Circuit-By-Circuit Guide To FCA Suits After High Court SnubThe U.S. Supreme Court's refusal to resolve one of the False Claims Act's most consequential controversies leaves circuit courts deeply divided over whistleblower pleading obligations in ways that will reverberate nationwide, attorneys say. Here, Law360 explores each circuit's approach and scenarios that might finally trigger high court intervention. 
- 
									Inside The Collapse Of A Pioneering Opioid Case For DOJThe U.S. Department of Justice launched a "terribly flawed" criminal case against a drug distributor and several individuals amid pressure to alleviate Appalachia's opioid crisis, and a newly confirmed U.S. attorney displayed "courage and guts" by ending the case last month, defense counsel told Law360 in an expansive interview. 
Expert Analysis
- 
								
								Fed. Circ. In September: The Printed Matter Doctrine Expands  The Federal Circuit’s recent decision in Bayer v. Mylan represents an extension of the doctrine that adding new words to an existing product or method will not support patentability unless there is a functional relationship, bringing new considerations for both patent holders and challengers, say attorneys at Knobbe Martens. 
- 
								
								Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split  In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor. 
- 
								Series Practicing Stoicism Makes Me A Better Lawyer  Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer. 
- 
								
								Broader Eligibility For AI-Related Patents May Be Coming  A series of recent developments from the U.S. Patent and Trademark Office appears to signal that claims involving improvement in the operation of a machine learning model are now more likely to be considered patent-eligible, and that patent examiners may focus on questions of novelty and nonobviousness and less so on subject matter eligibility, say attorneys at Kilpatrick. 
- 
								Series The Biz Court Digest: Texas, One Year In  A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker. 
- 
								
								AI Product Safety Insights May Expand Foreseeability  Product liability law has long held that companies are responsible for risks they knew about or should have known about — and with AI systems now able to assess and predict hazards during the design process, companies should expect that courts will likely treat such hazards as foreseeable, says Donald Fountain at Clark Fountain. 
- 
								Series Law School's Missed Lessons: Educating Your Community  Nearly two decades prosecuting scammers and elder fraud taught me that proactively educating the public about the risks they face and the rights they possess is essential to building trust within our communities, empowering otherwise vulnerable citizens and preventing wrongdoers from gaining a foothold, says Roger Handberg at GrayRobinson. 
- 
								
								Organ Transplant System Reforms Mark Regulatory Overhaul  Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render. 
- 
								
								Adapting To USPTO's Reduction Of Examiner Interview Time  Reported changes to the U.S. Patent and Trademark Office's examiner performance appraisal plan will likely make interviews scarcer throughout the application process, potentially influencing patent allowance rates and increasing the importance of approaching each interview with a clear agenda and well-defined goals, say attorneys at Polsinelli. 
- 
								
								Federal Grantees May Soon Face More Limitations On Speech  If courts accept the administration’s new interpretation of preexisting case law, which attempts to graft onto grant recipients the existing limitations on government contractors' free speech, a more deferential standard may soon apply in determining whether an agency’s refusal or termination of a grant was in violation of the First Amendment, say attorneys at Venable. 
- 
								
								5 Crisis Lawyering Skills For An Age Of Uncertainty  As attorneys increasingly face unprecedented and pervasive situations — from prosecutions of law enforcement officials to executive orders targeting law firms — they must develop several essential competencies of effective crisis lawyering, says Ray Brescia at Albany Law School. 
- 
								
								Anticipating FTC's Shift On Unfair Competition Enforcement  As the Federal Trade Commission signals that it will continue to challenge unfair or deceptive acts and practices under Section 5 of the FTC Act, but with higher evidentiary standards, attorneys counseling healthcare, technology, energy or pharmaceuticals clients should note several practice tips, says Thomas Stratmann at George Mason University. 
- 
								
								Insights From Recent Cases On Navigating Snap Removal  Snap removal, which allows defendants to transfer state court cases to federal court before a forum defendant is properly joined and served, is viewed differently across federal circuits — but keys to making it work can be drawn from recent decisions critiquing the practice, say attorneys at Perkins Coie. 
- 
								Opinion It's Time For The Judiciary To Fix Its Cybersecurity Problem  After recent reports that hackers have once again infiltrated federal courts’ electronic case management systems, the judiciary should strengthen its cybersecurity practices in line with executive branch standards, outlining clear roles and responsibilities for execution, says Ilona Cohen at HackerOne. 
- 
								Series Writing Novels Makes Me A Better Lawyer  Writing my debut novel taught me to appreciate the value of critique and to never give up, no matter how long or tedious the journey, providing me with valuable skills that I now emphasize in my practice, says Daniel Buzzetta at BakerHostetler.